drugset
drugset / Trial / NCT04657861

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

NCT04657861 ↗

Phase 0 Recruiting 36 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma

Timeline

Start
2022-05-03
Primary completion
2024-08-20
Completion
2027-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject APRIL CAR-T cells Cell therapy — Intravenous

Indications

plasma cell myeloma refractory plasma cell neoplasm